Developer docs
API playgroundTry for free, no card

Search company profiles

RetinalGenix Technologies

Full company profile

uuid0005gby

Namestring
RetinalGenix Technologies
Legal namestring
RetinalGenix Technologies Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic medical device and therapeutics company developing an integrated platform that pairs high-resolution, non-dilating retinal imaging with a proprietary DNA/RNA/GPS pharmacogenetic mapping capability for the early detection of ocular and systemic diseases. The product portfolio comprises the RetinalCam home/remote patient-activated monitoring device, a portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and two early-stage therapeutic candidates—RTG-2023 for dry AMD (currently in a clinical study) and RTG-2024 for Alzheimer's dementia. Core foundational IP is held under an exclusive worldwide sublicense from Sanovas Ophthalmology LLC, and the company operates through wholly-owned subsidiary DNA/GPS Inc., acquired in 2022.

Short descriptiontext

RetinalGenix Technologies is a pre-revenue R&D-stage medical device company developing retinal imaging combined with pharmacogenetic mapping for early detection of ocular and systemic diseases, including diabetic retinopathy, AMD, and Alzheimer's.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersApollo Beach, United States
HQ citystring
Apollo Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal imaging devices, pharmacogenetic mapping, ocular disease detection, genetic test kits, therapeutic drug development
Industry3 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Ophthalmic medical devices and diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Genetic Testing Kits Sales
TypeHardware Sales
Description

Sale of DNA/GPS oral swab laboratory test kits to patients through clinician offices, direct-to-consumers, and distributors. Planned launch late 2026. Third-party genetic testing company handles manufacturing, distribution, clinical processing and reporting.

ir.retinalgenix.com
2Retinal Imaging Platform
TypeHardware Sales
Description

Revenue from RetinalCam remote monitoring device and RetinalGeniX imaging system. RetinalCam planned for launch end of 2026. FDA clearance not required for RetinalCam as non-diagnostic screening tool.

ir.retinalgenix.com
3Therapeutic Drug Development
TypeOne Time License
Description

Development of pharmaceutical products RTG-2023 for dry AMD and RTG-2024 for Alzheimer's syndrome dementia. Drug candidate RTG-2023 in clinical study phase. Revenue potential through drug commercialization pending regulatory approval.

ir.retinalgenix.com
4Patient Database Services
TypeSubscription Recurring
Description

Secure, interoperable database system combining genetic and imaging data. Anonymized database for research purposes creating future IP opportunities. Patient-controlled access with HIPAA protections.

ir.retinalgenix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Genetic testing kits - pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

DNA/GPS laboratory home-use test kits to be sold via clinician offices, direct-to-consumers, and distributors. Specific pricing not disclosed publicly.

ir.retinalgenix.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1DNA/RNA/GPS™
Description

Proprietary pharmacogenetic mapping platform for screening, monitoring, and creating diagnostic markers for systemic and retinal disorders

ir.retinalgenix.com
+4 more records
Core offering1 text field

RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic company developing an integrated platform of medical devices, genetic testing, AI software, and therapeutic drug candidates. Its core offerings include the DNA/RNA/GPS Pharmaco-Genetic Mapping platform, the RetinalCam home/remote retinal monitoring device, the portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and therapeutic drug candidates RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's/dementia). The platform is designed for early, non-invasive, dilation-free detection of ocular and systemic diseases including AMD, diabetic retinopathy, glaucoma, Alzheimer's, Parkinson's, and cardiovascular conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 200 million people worldwide with AMD projected to reach 300 million by 2040
+4 more records
Product overview1 text field

RetinalGenix Technologies operates as an integrated four-pillar platform combining: (1) DNA/RNA/GPS Pharmaco-Genetic Mapping for genetic testing and biomarker discovery, (2) Retinal Imaging devices including the portable Retinal Imaging Screening Device and RetinalCam for home/remote monitoring, (3) the RECAD AI System for secure patient-controlled database combining genetic and imaging data, and (4) Therapeutic development including RTG-2023 for dry AMD and RTG-2024 for Alzheimer's dementia. The platform enables early disease detection through non-invasive retinal imaging and genetic profiling for ocular, neurodegenerative, cardiovascular, vascular, and metabolic conditions.

Product and service7 records
1RetinalCam
CategoryMedical device (remote retinal monitoring)
Description

In-home/remote, patient-activated retinal monitoring and imaging device that provides 24/7 real-time communication and physician alerts, designed for patient self-monitoring without pupil dilation. Targeted for deployment through pharmacies, clinics, hospitals, nursing homes, urgent care centers, walk-in clinics, doctors' offices, optical outlets, and home use.

2Retinal Imaging Screening Device
CategoryMedical device (retinal imaging)
Description

Portable, high-resolution retinal imaging system providing a wide field of view without requiring pupil dilation, designed for cost-effective mass screening of ocular, neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.

3DNA/RNA/GPS Pharmaco-Genetic Mapping Platform
CategoryGenetic testing / pharmacogenetic platform
Description

Proprietary pharmacogenetic mapping platform that screens, monitors, and generates data for profiling, trend identification, and diagnostic markers for systemic and retinal disorders using DNA and RNA biomarkers; supports drug repositioning and validation.

4RECAD AI System (RetinalGenix Eye Care Anonymized AI Database)
5RTG-2023
CategoryTherapeutic drug candidate
Description

Therapeutic drug candidate in development for the treatment of dry age-related macular degeneration (dry AMD), intended to prevent progression from dry to wet AMD. Currently in clinical study phase with 490 patients enrolled.

6RTG-2024
CategoryTherapeutic drug candidate
Description

Therapeutic drug candidate in development for the treatment of Alzheimer's syndrome dementia, with a provisional patent submitted in November 2023 targeting the root causes of disease at the molecular and cellular level.

7DNA/GPS Oral Swab Genetic Test Kit
CategoryGenetic test kit (consumer/clinical)
Description

Home-use oral swab genetic test kit sold through clinician offices, direct-to-consumer channels, and distributors, designed to enable personalized genetic profiling tied to the DNA/RNA/GPS Pharmaco-Genetic Mapping platform.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-16
Description

Collaboration to develop early detection biomarkers for diseases using retinal imaging and proteomic profiling. Aims to improve diagnosis and monitoring of neurodegenerative, systemic, and retinal diseases including Alzheimer's and Parkinson's by integrating RetinalGenix's non-invasive retinal imaging platform with Seer Bio's proteomic profiling technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Strategic partnership to combine retinal imaging technology with clinical-grade DNA genotyping for early detection of neurodegenerative, systemic, and retinal diseases including AMD, glaucoma, diabetic retinopathy, Alzheimer's, and Parkinson's. Plans for commercial deployment in primary care offices, clinics, and ophthalmology settings, along with healthcare payer partnerships for preventative care coverage.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-05-05
Description

Laboratory lease agreement with MBC BioLabs in San Carlos, California. Company will use the facility to develop its DNA/RNA/GPS Pharmaco-Genetic Mapping platform and repurpose drugs for dementia, parkinsonism, and macular degeneration. Option for Mission BioCapital to invest.

4Pearl IRB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-30
Description

Institutional Review Board engaged to conduct study for personalizing medical evaluations for patients receiving intraocular injections for wet macular degeneration. Study aims to determine genetic basis for treatment success/failure and help patients evaluate treatment necessity. Enrolling up to 100 patients in 2026 with expansion to multistate physicians planned for winter 2026.

ir.retinalgenix.com
5Seven Springs Surgery Center
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-10-01
Description

Engaged phlebotomists from Seven Springs Surgery Center to facilitate blood draw process necessary for the Pearl IRB study.

ir.retinalgenix.com
6Avania Clinical
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-01-01
Description

Contracted as initial advisor for therapeutic drug development, specifically for RTG-2023 and RTG-2024 product candidates.

ir.retinalgenix.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-06-24
Description

Amended and Restated Master Services Agreement for software design, engineering, and regulatory services related to RetinalCam and RetinalGeniX. Agreement renewed in 2025 to support ongoing new camera system development.

8Sanovas Ophthalmology LLC
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-06-24
Description

Sublicense agreement granting exclusive worldwide license to intellectual property including six patents, two patent applications, and two trademark applications relating to eye and ocular visualization and monitoring. Royalty of mid-single digit percentage of Net Sales. CEO Jerry Katzman is managing member of Sanovas.

ir.retinalgenix.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RetinalGenix Technologies

Ophthalmic medical devices and diagnosticsretinalgenix.com

RetinalGenix Technologies is a pre-revenue R&D-stage medical device company developing retinal imaging combined with pharmacogenetic mapping for early detection of ocular and systemic diseases, including diabetic retinopathy, AMD, and Alzheimer's.

What RetinalGenix Technologies does

RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic medical device and therapeutics company developing an integrated platform that pairs high-resolution, non-dilating retinal imaging with a proprietary DNA/RNA/GPS pharmacogenetic mapping capability for the early detection of ocular and systemic diseases. The product portfolio comprises the RetinalCam home/remote patient-activated monitoring device, a portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and two early-stage therapeutic candidates—RTG-2023 for dry AMD (currently in a clinical study) and RTG-2024 for Alzheimer's dementia. Core foundational IP is held under an exclusive worldwide sublicense from Sanovas Ophthalmology LLC, and the company operates through wholly-owned subsidiary DNA/GPS Inc., acquired in 2022.

RetinalGenix Technologies firmographics

Firmographics
Name
RetinalGenix Technologies
Legal name
RetinalGenix Technologies Inc.
Website
https://retinalgenix.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
RetinalGenix Technologies is a pre-revenue R&D-stage medical device company developing retinal imaging combined with pharmacogenetic mapping for early detection of ocular and systemic diseases, including diabetic retinopathy, AMD, and Alzheimer's.
Ownership category
akta.pro rank

RetinalGenix Technologies industry classification

Industry
Product category
Ophthalmic medical devices and diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Retinal imaging devices
  • Pharmacogenetic mapping
  • Ocular disease detection
  • Genetic test kits
  • Therapeutic drug development

Where RetinalGenix Technologies is headquartered

Location

Headquarters

HQ city
Apollo Beach
HQ country
United States
HQ region
North America

Offices3 records

Markets served

RetinalGenix Technologies business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Genetic Testing Kits Sales: Sale of DNA/GPS oral swab laboratory test kits to patients through clinician offices, direct-to-consumers, and distributors. Planned launch late 2026. Third-party genetic testing company handles manufacturing, distribution, clinical processing and reporting.
  2. Retinal Imaging Platform: Revenue from RetinalCam remote monitoring device and RetinalGeniX imaging system. RetinalCam planned for launch end of 2026. FDA clearance not required for RetinalCam as non-diagnostic screening tool.
  3. Therapeutic Drug Development: Development of pharmaceutical products RTG-2023 for dry AMD and RTG-2024 for Alzheimer's syndrome dementia. Drug candidate RTG-2023 in clinical study phase. Revenue potential through drug commercialization pending regulatory approval.
  4. Patient Database Services: Secure, interoperable database system combining genetic and imaging data. Anonymized database for research purposes creating future IP opportunities. Patient-controlled access with HIPAA protections.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goGenetic testing kits - pricing not publicly disclosed

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

RetinalGenix Technologies product offering

Product offering

Core offering

RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic company developing an integrated platform of medical devices, genetic testing, AI software, and therapeutic drug candidates. Its core offerings include the DNA/RNA/GPS Pharmaco-Genetic Mapping platform, the RetinalCam home/remote retinal monitoring device, the portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and therapeutic drug candidates RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's/dementia). The platform is designed for early, non-invasive, dilation-free detection of ocular and systemic diseases including AMD, diabetic retinopathy, glaucoma, Alzheimer's, Parkinson's, and cardiovascular conditions.

Product overview

RetinalGenix Technologies operates as an integrated four-pillar platform combining: (1) DNA/RNA/GPS Pharmaco-Genetic Mapping for genetic testing and biomarker discovery, (2) Retinal Imaging devices including the portable Retinal Imaging Screening Device and RetinalCam for home/remote monitoring, (3) the RECAD AI System for secure patient-controlled database combining genetic and imaging data, and (4) Therapeutic development including RTG-2023 for dry AMD and RTG-2024 for Alzheimer's dementia. The platform enables early disease detection through non-invasive retinal imaging and genetic profiling for ocular, neurodegenerative, cardiovascular, vascular, and metabolic conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • DNA/RNA/GPS™: Proprietary pharmacogenetic mapping platform for screening, monitoring, and creating diagnostic markers for systemic and retinal disorders
  • RetinalCam™
  • RECAD™ AI System
  • RetinalGeniX™
  • RetinalGenix RetinalCam

Products and services

  • RetinalCam In-home/remote, patient-activated retinal monitoring and imaging device that provides 24/7 real-time communication and physician alerts, designed for patient self-monitoring without pupil dilation. Targeted for deployment through pharmacies, clinics, hospitals, nursing homes, urgent care centers, walk-in clinics, doctors' offices, optical outlets, and home use.
  • Retinal Imaging Screening Device Portable, high-resolution retinal imaging system providing a wide field of view without requiring pupil dilation, designed for cost-effective mass screening of ocular, neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
  • DNA/RNA/GPS Pharmaco-Genetic Mapping Platform Proprietary pharmacogenetic mapping platform that screens, monitors, and generates data for profiling, trend identification, and diagnostic markers for systemic and retinal disorders using DNA and RNA biomarkers; supports drug repositioning and validation.
  • RECAD AI System (RetinalGenix Eye Care Anonymized AI Database)
  • RTG-2023 Therapeutic drug candidate in development for the treatment of dry age-related macular degeneration (dry AMD), intended to prevent progression from dry to wet AMD. Currently in clinical study phase with 490 patients enrolled.
  • RTG-2024 Therapeutic drug candidate in development for the treatment of Alzheimer's syndrome dementia, with a provisional patent submitted in November 2023 targeting the root causes of disease at the molecular and cellular level.
  • DNA/GPS Oral Swab Genetic Test Kit Home-use oral swab genetic test kit sold through clinician offices, direct-to-consumer channels, and distributors, designed to enable personalized genetic profiling tied to the DNA/RNA/GPS Pharmaco-Genetic Mapping platform.

Quantifiable outcome

  • 200 million people worldwide with AMD projected to reach 300 million by 2040
  • +4 more outcomes

Companies that use RetinalGenix Technologies

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

RetinalGenix Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

RetinalGenix Technologies partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Seer, Inc.coreTechnology or Integration · 16 October 2025Collaboration to develop early detection biomarkers for diseases using retinal imaging and proteomic profiling. Aims to improve diagnosis and monitoring of neurodegenerative, systemic, and retinal diseases including Alzheimer's and Parkinson's by integrating RetinalGenix's non-invasive retinal imaging platform with Seer Bio's proteomic profiling technology.
  • RGEN Inc. (RGEN Clinical Genotyping Laboratory)coreStrategic or Co-development Partner · 1 October 2025Strategic partnership to combine retinal imaging technology with clinical-grade DNA genotyping for early detection of neurodegenerative, systemic, and retinal diseases including AMD, glaucoma, diabetic retinopathy, Alzheimer's, and Parkinson's. Plans for commercial deployment in primary care offices, clinics, and ophthalmology settings, along with healthcare payer partnerships for preventative care coverage.
  • MBC BioLabscoreImplementation/ SI/ Consulting Partner · 5 May 2025Laboratory lease agreement with MBC BioLabs in San Carlos, California. Company will use the facility to develop its DNA/RNA/GPS Pharmaco-Genetic Mapping platform and repurpose drugs for dementia, parkinsonism, and macular degeneration. Option for Mission BioCapital to invest.
  • Pearl IRBcoreStrategic or Co-development Partner · 30 October 2023Institutional Review Board engaged to conduct study for personalizing medical evaluations for patients receiving intraocular injections for wet macular degeneration. Study aims to determine genetic basis for treatment success/failure and help patients evaluate treatment necessity. Enrolling up to 100 patients in 2026 with expansion to multistate physicians planned for winter 2026.
  • Seven Springs Surgery CenterminorImplementation/ SI/ Consulting Partner · 1 October 2023Engaged phlebotomists from Seven Springs Surgery Center to facilitate blood draw process necessary for the Pearl IRB study.
  • Avania ClinicalcoreImplementation/ SI/ Consulting Partner · 1 January 2023Contracted as initial advisor for therapeutic drug development, specifically for RTG-2023 and RTG-2024 product candidates.
  • ADM Tronics Unlimited, Inc.coreTechnology or Integration · 24 June 2021Amended and Restated Master Services Agreement for software design, engineering, and regulatory services related to RetinalCam and RetinalGeniX. Agreement renewed in 2025 to support ongoing new camera system development.
  • Sanovas Ophthalmology LLCcoreOEM/ Whitelabel/ Licensing Partner · 24 June 2021Sublicense agreement granting exclusive worldwide license to intellectual property including six patents, two patent applications, and two trademark applications relating to eye and ocular visualization and monitoring. Royalty of mid-single digit percentage of Net Sales. CEO Jerry Katzman is managing member of Sanovas.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

RetinalGenix Technologies competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

RetinalGenix Technologies social profiles

Digital presence

RetinalGenix Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RetinalGenix Technologies leadership team

Management profile

Number of profiles

Profiles2 records

RetinalGenix Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

RetinalGenix Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RetinalGenix Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RetinalGenix Technologies

What does RetinalGenix Technologies do?

RetinalGenix Technologies is a pre-revenue, R&D-stage ophthalmic company developing an integrated platform of medical devices, genetic testing, AI software, and therapeutic drug candidates. Its core offerings include the DNA/RNA/GPS Pharmaco-Genetic Mapping platform, the RetinalCam home/remote retinal monitoring device, the portable Retinal Imaging Screening Device, the RECAD AI patient-controlled database, and therapeutic drug candidates RTG-2023 (dry AMD) and RTG-2024 (Alzheimer's/dementia). The platform is designed for early, non-invasive, dilation-free detection of ocular and systemic diseases including AMD, diabetic retinopathy, glaucoma, Alzheimer's, Parkinson's, and cardiovascular conditions.

Is RetinalGenix Technologies a public or private company?

RetinalGenix Technologies is a public company. It is classified as public and is currently operating.

When was RetinalGenix Technologies founded?

RetinalGenix Technologies was founded in 2017. It employs 1 to 10 people.

Where is RetinalGenix Technologies based?

RetinalGenix Technologies is headquartered in Apollo Beach, United States, in the North America region.

How does RetinalGenix Technologies make money?

Four revenue lines are on record. Genetic Testing Kits Sales are the primary driver. The others are retinal Imaging Platform, therapeutic Drug Development and patient Database Services.

Does RetinalGenix Technologies have an API?

No public API is recorded for RetinalGenix Technologies.

What industry is RetinalGenix Technologies in?

RetinalGenix Technologies's product category is Ophthalmic medical devices and diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COORetinalGenix Technologies agreed to hire M. Cory Zwerling as CFO and interim COO, effective January 1, 2026. The company seeks a leader with healthcare and finance experience to guide its transition from R&D to early commercial operations. Zwerling brings over three decades of experience in pharmaceuticals, medical imaging, and biotechnology.GlobeNewswireRetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COORetinalGenix Technologies Inc. has signed an agreement to hire M. Cory Zwerling as chief financial officer and interim chief operating officer, effective January 1, 2026. Zwerling brings more than three decades of global experience in healthcare, finance, and operations, including leadership roles at Bristol-Myers Squibb Medical Imaging and executive positions at healthcare technology companies. The company stated this appointment is designed to support its transition from R&D into early commercial operations.GlobeNewswireRetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal DiseasesRetinalGenix Technologies announced a collaboration with Seer, Inc. to develop early detection biomarkers for diseases using retinal imaging and proteomic profiling. The partnership aims to improve diagnosis and monitoring of neurodegenerative, systemic, and retinal diseases, including Alzheimer’s and Parkinson’s.GlobeNewswireRetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal DiseasesRetinalGenix Technologies Inc. and RGEN Inc. announced a strategic partnership on October 1, 2025, to combine retinal imaging technology with clinical-grade DNA genotyping for early detection of neurodegenerative, systemic, and retinal diseases including AMD, glaucoma, diabetic retinopathy, Alzheimer's, and Parkinson's. The collaboration aims to develop predictive models and deploy a scalable population-based screening platform by integrating RetinalGenix's high-resolution imaging with RGEN's CLIA-certified genetic testing capabilities. The companies stated plans for commercial deployment in primary care offices, clinics, and ophthalmology settings, along with partnerships with healthcare payers for preventative care coverage.The Manila TimesRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease CareRetinalGenix Technologies announced a recently granted patent for real-time home and remote ocular monitoring, including expanded peripheral retinal mapping and biomarkers like beta-amyloid. The company plans to integrate its DNA/RNA/GPS Pharmaco-Genetic Mapping platform with its high-resolution retinal imaging system to enable 24/7 health data access and reduce office visits.GlobeNewswireRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease CareRetinalGenix Technologies announced recent patent grants covering real-time home and remote ocular monitoring and physician alert systems. The patents expand peripheral retinal mapping and include biomarkers like beta-amyloid for Alzheimer's. The company plans to integrate its DNA/RNA/GPS mapping platform with its retinal imaging system for early disease detection.GlobeNewswireRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease CareRetinalGenix Technologies announced a recently granted patent for real-time home and remote ocular monitoring, including expanded peripheral retinal mapping and biomarkers like beta-amyloid. The company plans to integrate its DNA/RNA/GPS Pharmaco-Genetic Mapping platform with its high-resolution retinal imaging system to enable 24/7 health data access and reduce office visits.Stock TitanRetinalGenix Secures Patent for Remote Eye Disease Monitoring SystemRetinalGenix Technologies announced a recently granted patent for a remote eye disease monitoring system, covering real-time home monitoring and physician alert systems. The patent expands peripheral retinal mapping to detect early diabetic changes and Alzheimer's biomarkers, and plans to integrate with its DNA/RNA/GPS mapping platform. The company expects the system to reduce office visits and enable 24/7 health data access.GlobeNewswireRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease CareRetinalGenix Technologies announced recent patent grants for home and remote ocular monitoring, including a 2023 filing for peripheral retinal mapping. The patents support real-time imaging and biomarker detection for diseases like diabetes and Alzheimer's. The company plans to integrate its DNA/RNA/GPS mapping platform with its retinal imaging system for clinical triage.YahooRetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease CareRetinalGenix Technologies announced new patents for home and remote ocular monitoring, including a 2023 filing approved after three years. The patents cover real-time retinal imaging and biomarkers like beta-amyloid, with a planned integration of its DNA/RNA/GPS mapping platform to enable early disease detection and reduce office visits.